On July 8, 2026, Candel Therapeutics, Inc. revealed that the Compensation Committee of its Board of Directors awarded Mark Sims, the new Chief Commercial Officer, stock options to buy 285,000 shares of common stock at an exercise price of $10.03 per share. The grant matches the closing price of Candel's common stock on The Nasdaq Global Market on July 6, 2026. Candel is a Nasdaq-listed clinical-stage biopharmaceutical firm with a focus on developing multimodal immunotherapies for enhancing cancer patient outcomes.
